Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1][1][1] Summary by Relevant Sections Class Action Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, can seek to be lead plaintiffs in the class action lawsuit, which is titled Bailey v. Ultragenyx Pharmaceutical Inc. [1][1] - The lawsuit alleges that Ultragenyx and its executives made false statements about the reliability of data from the Phase III Orbit study, which was intended to show the drug's effectiveness [1][1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a misleading impression of having reliable information regarding the effects of setrusumab while downplaying the risks associated with the Phase III Orbit study [1][1] - It is alleged that the company failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived effectiveness of the treatment [1][1] Stock Price Impact - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by more than 25% [1][1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by over 42% [1][1] Legal Process for Lead Plaintiffs - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of all class members [1][1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1][1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1][1]

Avidity Biosciences, Inc. (formerly NASDAQ: RNA, temporarily RNAM) is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) for serious diseases, including rare genetic cardiomyopathies and neuromuscular disorders. On February 23, 2026, Avidity announced it would convene its special stockholder meeting as scheduled and immediately adjourn it without conducting business. The meeting reconvened on February 26, 2026, ...

（图片来源：摄图网） 2月25日，长春高新技术产业(集团)股份有限公司发布公告，其子公司长春金赛药业有限责任公司自主研发 的GenSci141软膏临床试验申请获得国家药品监督管理局(NMPA)批准。该药物适应症为用于改善因多种原因 导致的儿童小阴茎，这是全球首款针对儿童小阴茎的特异性治疗药物，标志着这一长期缺乏标准药物治疗的 领域迎来历史性突破。 不过，面对市场热捧，长春高新保持审慎态度。2月26日，公司方面对《每日经济新闻》记者表示："这个项 目还处于早期阶段，目前没有能对外交流的信息。"同日，长春高新董秘办相关人士进一步说明："目前该药 物只是拿到了临床试验的批准，暂未开始进行临床研究。上市时间还不确定，后续从临床试验、上市申报再 到最终获批上市还需较长时间。" 这种审慎并非多余。创新药研发素有"双十定律"之称——即耗时10年、投入10亿美元，且失败率极高。目前 GenSci141仅获批开展临床试验，距离真正的商业化落地还有临床I-III期及上市审批等多道关卡。 曾几何时，国内儿童用药长期依赖进口，从生长激素到罕见病药物，跨国药企占据绝对主导地位;如今，以 长春高新、百济神州、信达生物等为代表的创新药企， ...

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Best All-Time Low Stocks to Invest In Now. Wall Street is bullish on Telix Pharmaceuticals Limited (NASDAQ:TLX) after the company released its full-year 2025 results on February 19. ​Recently, on February 23, John Hester from Bell Potter reiterated a Buy rating on the stock with a price target of AU$19. On the same day, David Bailey from Morgan Stanley also reiterated a Buy rating on the stock with a price target of AU$25.6. ​In fiscal 2025, the ...

Core Viewpoint - Hemogenyx Pharmaceuticals plc has announced its total issued share capital and the number of voting rights as of February 27, 2026, indicating a stable share structure for the company [1]. Group 1 - The total issued share capital of Hemogenyx Pharmaceuticals consists of 6,425,429 ordinary shares, each with a nominal value of 1 penny [1]. - There are no shares held in treasury, which means all issued shares are available for voting [1]. - The total number of voting rights in the company is equal to the total issued shares, amounting to 6,425,429 [1].

Core Insights - Ionis Pharmaceuticals, Inc. (IONS) has experienced a significant rally in its stock price following the positive data release for its drug Tryngolza (olezarsen), which treats severe hypertriglyceridemia, indicating it may become the new standard of care [2] Group 1: Company Performance - The strong data from Tryngolza suggests a promising future for Ionis Pharmaceuticals, potentially positioning the company as a leader in the treatment of familial chylomicronemia syndrome [2] - The market analyst Bret Jensen, with over 13 years of experience, highlights the potential for high returns in the biotech sector, particularly through investments in companies like Ionis [2] Group 2: Investment Opportunities - The Biotech Forum, led by Bret Jensen, offers a model portfolio featuring 12-20 high upside biotech stocks, including Ionis, and provides live discussions on trade ideas and weekly market commentary [2]

During the question-and-answer session, management addressed the quarter-end inventory build. Auerbach said Puma tends to see inventory building in the fourth quarter “since launch,” and attributed much of the pattern to channel purchasing ahead of an assumed price increase at the start of the year. Chief Financial Officer Maximo Nougues added that Puma typically expects that inventory to burn off in the first quarter, which is one reason management described Q1 as “usually the lowest quarter of the year” f ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small-cap stocks with huge growth potential. Nuvation Bio Inc. (NYSE:NUVB) announced on February 9 the finalization of a protocol amendment to the ongoing global SIGMA study of safusidenib that expands it to a Phase 3 trial. Safusidenib is a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, and SIGMA is involved in the evaluation of the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high ...

Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on Insmed Incorporated (NASDAQ:INSM) to $204 from $211 on February 24, maintaining an Outperform rating on the shares. The rating update came after the fiscal Q4 report, with the firm stating that the company offered “highly positive comments” on the Brinsupri launch. Insmed (INSM) Soars After Raising $650 million Insmed Incorporated (NASDAQ:INSM) reported its fiscal Q4 and full yea ...

On execution, the company described building an integrated commercial organization supported by sales, medical affairs, nurse educators, field reimbursement specialists, and its CrinetiCARE nurse-staffed support program. Chief Commercial Officer Isabel Kalofonos said feedback is centering on efficacy and symptom control, and she noted physicians and patients are responding to the drug’s observed “patterns of action and the symptom controls,” including that it “works in two to four weeks.”Struthers said adop ...